These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20922338)

  • 1. Health economics and health policy issues in Alzheimer's disease.
    Rapp T
    J Nutr Health Aging; 2010 Oct; 14(8):630-2. PubMed ID: 20922338
    [No Abstract]   [Full Text] [Related]  

  • 2. The Real-World Medicare Costs of Alzheimer Disease: Considerations for Policy and Care.
    Pyenson B; Sawhney TG; Steffens C; Rotter D; Peschin S; Scott J; Jenkins E
    J Manag Care Spec Pharm; 2019 Jul; 25(7):800-809. PubMed ID: 31232206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public policy toward special dementia care units.
    Phillips CD
    Alzheimer Dis Assoc Disord; 1994; 8 Suppl 1():S405-7. PubMed ID: 8068286
    [No Abstract]   [Full Text] [Related]  

  • 4. Toward a policy research agenda for special care units.
    Lindeman D; Beitler D; Lombardo NE
    Alzheimer Dis Assoc Disord; 1994; 8 Suppl 1():S395-404. PubMed ID: 8068285
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic outcomes and levers: impacts for individuals and society.
    Knapp M
    Int Psychogeriatr; 2007 Jun; 19(3):483-95. PubMed ID: 17391570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contingent valuation method in health care. An economic evaluation of Alzheimer's disease.
    Nocera S; Telser H; Bonato D
    Dev Health Econ Public Policy; 2003; 8():iii-xi, 1-116. PubMed ID: 15027158
    [No Abstract]   [Full Text] [Related]  

  • 7. Direct and indirect cost of managing alzheimer's disease and related dementias in the United States.
    Deb A; Thornton JD; Sambamoorthi U; Innes K
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):189-202. PubMed ID: 28351177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between severity of Alzheimer's disease and costs of caring.
    Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
    CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Epidemiology of Dementia and Alzheimer Disease in Portugal: Estimations of Prevalence and Treatment-Costs].
    Santana I; Farinha F; Freitas S; Rodrigues V; Carvalho Å
    Acta Med Port; 2015; 28(2):182-8. PubMed ID: 26061508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina.
    Allegri RF; Butman J; Arizaga RL; Machnicki G; Serrano C; Taragano FE; Sarasola D; Lon L
    Int Psychogeriatr; 2007 Aug; 19(4):705-18. PubMed ID: 16870037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic considerations of Alzheimer's disease and related disorders.
    Michel JP; Zekry D; Mulligan R; Giacobini E; Gold G
    Aging (Milano); 2001 Jun; 13(3):255-60. PubMed ID: 11442307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The economic and social costs of dementia].
    Washimi Y; Ohta T
    Nihon Ronen Igakkai Zasshi; 2004 Sep; 41(5):451-9. PubMed ID: 15515718
    [No Abstract]   [Full Text] [Related]  

  • 14. Confronting the crisis in dementia care.
    Lancet Neurol; 2009 May; 8(5):413. PubMed ID: 19375658
    [No Abstract]   [Full Text] [Related]  

  • 15. Special topic section on health economics and public policy of Alzheimer's disease.
    Jönsson L; Lin PJ; Khachaturian AS
    Alzheimers Dement; 2017 Mar; 13(3):201-204. PubMed ID: 28232007
    [No Abstract]   [Full Text] [Related]  

  • 16. Dependence Stage and Pharmacoeconomic Outcomes in Patients With Alzheimer Disease.
    Michaud TL; High R; Charlton ME; Murman DL
    Alzheimer Dis Assoc Disord; 2017; 31(3):209-217. PubMed ID: 28486240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic literature review of methodologies and data sources of existing economic models across the full spectrum of Alzheimer's disease and dementia from apparently healthy through disease progression to end of life care: a systematic review protocol.
    Karagiannidou M; Wittenberg R; Landeiro FIT; Park AL; Fry A; Knapp M; Gray AM; Tockhorn-Heidenreich A; Castro Sanchez AY; Ghinai I; Handels R; Lecomte P; Wolstenholme J;
    BMJ Open; 2018 Jun; 8(6):e020638. PubMed ID: 29884696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing Treatment Guidelines for Alzheimer's Disease and Other Dementias.
    Rabins PV
    J Clin Psychiatry; 1998; 59 Suppl 11():17-9. PubMed ID: 9731546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economics: basic principles and application in mental health.
    Suh GH
    Int Psychogeriatr; 2007 Dec; 19(6):993-1002. PubMed ID: 18161066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.